Galapagos | GLPG - Cash And Equivalent


Galapagos reported EUR87.87M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
argenx SE USD 4.3B 2.21B Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Incyte USD 3.58B 650.78M Dec/2025
Merck EUR 2.25B 1.08B Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025